dc.creatorIñíguez Vila, Germán
dc.creatorRomán, Rossana
dc.creatorYoulton, Ronald
dc.creatorCassorla Goluboff, Fernando
dc.creatorMericq, Verónica
dc.date.accessioned2019-03-11T13:00:58Z
dc.date.available2019-03-11T13:00:58Z
dc.date.created2019-03-11T13:00:58Z
dc.date.issued2011
dc.identifierHormone Research in Paediatrics, Volumen 75, Issue 2, 2018, Pages 94-100
dc.identifier16632818
dc.identifier16632826
dc.identifier10.1159/000317429
dc.identifierhttps://repositorio.uchile.cl/handle/2250/165188
dc.description.abstractBackground: Novel molecular insights have suggested that ghrelin may be involved in the pathogenesis of some forms of short stature. Recently, growth hormone secretagogue receptor (GHSR) mutations that segregate with short stature have been reported. Aim: To study plasma ghrelin levels in prepubertal patients with idiopathic short stature (ISS). Methods: Fasting total plasma ghrelin levels (radioimmunoassay) in 41 prepubertal patients with ISS (18 females, age 7.9 ± 0.5 years) compared with 42 age- and sex-matched controls (27 females, age 8.0 ± 0.3 years) with normal height. In a subset of 28 patients, the ghrelin receptor was sequenced. Results: ISS patients exhibited a higher level of ghrelin (1,458 ± 137 vs. 935 ± 55 pg/ml, p < 0.01) and similar IGF-I levels (-0.66 ± 1.29 vs. -0.32 ± 0.78 SDS) compared to controls. Ten patients with ISS had ghrelin levels greater than +2 SDS compared to controls. These patients did not differ in height, BMI or IGF-I SDS compared to ISS patients wit
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceHormone Research in Paediatrics
dc.subjectGhrelin
dc.subjectGrowth hormone secretagogue receptor
dc.subjectIdiopathic short stature
dc.titleGhrelin plasma levels in patients with idiopathic short stature
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución